BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...financing in blue, deals in purple and competitor clinical data in yellow. 7/15/13 - After MethylGene Inc....
...to reach the market since its formation almost 25 years ago. Mirati was founded as MethylGene Inc....
...during its first two years on NASDAQ. However, only one of the programs from its MethylGene...
BioCentury | Sep 21, 2015
Finance

California raisin'

...expects its broadened investor base has supplied enough cash to last into 2H17. Mirati (then MethylGene Inc....
BioCentury | Dec 16, 2013
Clinical News

Mocetinostat: Phase II started

...In 2009, FDA lifted a partial clinical hold on mocetinostat for cancer after Mirati (formerly MethylGene Inc....
BioCentury | Oct 25, 2013
Financial News

Mirati raises $56.9 million in bumped-up follow-on

...at $17.50 in a bumped-up follow-on underwritten by Jefferies; Leerink; and Piper Jaffray. Mirati (formerly MethylGene Inc....
BioCentury | Oct 17, 2013
Financial News

Portola, Mirati amend follow-ons

...at $14.50 per share in May, was up $2.72 (12%) on the day. Mirati (formerly MethylGene Inc....
BioCentury | Jul 29, 2013
Financial News

Mirati Therapeutics financial update

...The company reincorporated in the U.S. from Canada and changed its name to Mirati from MethylGene Inc....
BioCentury | Jul 15, 2013
Company News

Mirati Therapeutics cancer, infectious news

MethylGene Inc. completed its plans to reincorporate the company in the U.S. from Canada and change its name to Mirati. The biotech has applied to list its shares on NASDAQ and expects to start trading...
BioCentury | Jun 10, 2013
Clinical News

Mocetinostat: Phase II data

...in Chicago. In 2009, FDA lifted a partial clinical hold on mocetinostat for cancer after MethylGene...
...mocetinostat in certain Asian countries. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. MethylGene Inc....
BioCentury | Jun 10, 2013
Clinical News

Mocetinostat: Additional Phase II data

...28, 2010). In 2009, FDA lifted a partial clinical hold on mocetinostat for cancer after MethylGene...
...Otsuka Holdings Co. Ltd. (Tokyo:4578, Tokyo, Japan), has rights to mocetinostat in certain Asian countries. MethylGene Inc....
BioCentury | May 20, 2013
Company News

MethylGene cancer, infectious news

...area. The proposal, which includes a 1-for-50 reverse split, is subject to shareholder approval at MethylGene's...
...special meeting on June 25; the proposal is expected to be completed in early July. MethylGene...
...tax issues for U.S. shareholders and provide greater opportunity to attract and retain key personnel. MethylGene's...
Items per page:
1 - 10 of 206
BioCentury | Oct 26, 2019
Product Development

How a KRAS program transformed Mirati's story

...financing in blue, deals in purple and competitor clinical data in yellow. 7/15/13 - After MethylGene Inc....
...to reach the market since its formation almost 25 years ago. Mirati was founded as MethylGene Inc....
...during its first two years on NASDAQ. However, only one of the programs from its MethylGene...
BioCentury | Sep 21, 2015
Finance

California raisin'

...expects its broadened investor base has supplied enough cash to last into 2H17. Mirati (then MethylGene Inc....
BioCentury | Dec 16, 2013
Clinical News

Mocetinostat: Phase II started

...In 2009, FDA lifted a partial clinical hold on mocetinostat for cancer after Mirati (formerly MethylGene Inc....
BioCentury | Oct 25, 2013
Financial News

Mirati raises $56.9 million in bumped-up follow-on

...at $17.50 in a bumped-up follow-on underwritten by Jefferies; Leerink; and Piper Jaffray. Mirati (formerly MethylGene Inc....
BioCentury | Oct 17, 2013
Financial News

Portola, Mirati amend follow-ons

...at $14.50 per share in May, was up $2.72 (12%) on the day. Mirati (formerly MethylGene Inc....
BioCentury | Jul 29, 2013
Financial News

Mirati Therapeutics financial update

...The company reincorporated in the U.S. from Canada and changed its name to Mirati from MethylGene Inc....
BioCentury | Jul 15, 2013
Company News

Mirati Therapeutics cancer, infectious news

MethylGene Inc. completed its plans to reincorporate the company in the U.S. from Canada and change its name to Mirati. The biotech has applied to list its shares on NASDAQ and expects to start trading...
BioCentury | Jun 10, 2013
Clinical News

Mocetinostat: Phase II data

...in Chicago. In 2009, FDA lifted a partial clinical hold on mocetinostat for cancer after MethylGene...
...mocetinostat in certain Asian countries. Celgene Corp. (NASDAQ:CELG, Summit, N.J.) markets Vidaza azacitidine for MDS. MethylGene Inc....
BioCentury | Jun 10, 2013
Clinical News

Mocetinostat: Additional Phase II data

...28, 2010). In 2009, FDA lifted a partial clinical hold on mocetinostat for cancer after MethylGene...
...Otsuka Holdings Co. Ltd. (Tokyo:4578, Tokyo, Japan), has rights to mocetinostat in certain Asian countries. MethylGene Inc....
BioCentury | May 20, 2013
Company News

MethylGene cancer, infectious news

...area. The proposal, which includes a 1-for-50 reverse split, is subject to shareholder approval at MethylGene's...
...special meeting on June 25; the proposal is expected to be completed in early July. MethylGene...
...tax issues for U.S. shareholders and provide greater opportunity to attract and retain key personnel. MethylGene's...
Items per page:
1 - 10 of 206